NCT05366816View on ClinicalTrials.gov

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 17, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Sunitinib

37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.

DRUG

Regorafenib

120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.

Trial Locations (1)

33136

RECRUITING

University of Miami, Miami

All Listed Sponsors
lead

University of Miami

OTHER